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TYPE OF DIABETES AND ADHERENCE TO 
SELF-MONITORING OF BLOOD GLUCOSE
(SMBG)
Vincze G, Barner JC, Lopez DA
University of Texas at Austin, Austin,TX, USA
OBJECTIVES: To assess the demographic, biological,
and psychosocial differences between type 1 and type 2
diabetics with respect to SMBG adherence. METHODS:
A self-administered questionnaire was used to collect
demographic (age, gender, income, race/ethnicity, educa-
tion, and marital status), biological (duration of diabetes,
comorbidities, health status, diabetes-related symptoms,
and Health care utilization) and psychosocial (physical
inﬂuence, self-efﬁcacy, outcome expectations, environ-
mental barriers, community resources, social support,
and insurance coverage) information as well as SMBG
adherence. Adherence was dichotomized using 80% as
the cut-off level. Diabetics from a county family clinic
completed the survey during several educational semi-
nars. T-test, Pearson’s chi-square and logistic regression
analyses were used and the level of statistical signiﬁcance
was set at .05. RESULTS: Most participants (n = 213)
were female (66.0%), with type 2 (77.1%) diabetes and
were 57.1 (SD: 12.5) years old. Adherence to SMBG was
signiﬁcantly higher among participants with type 1 com-
pared to participants with type 2 diabetes (68.4% (SD:
41.8) and 49.2% (SD: 40.3), respectively). Both sub-
groups perceived “environmental barriers” (e.g., incon-
venience, painfulness, and cost) as a signiﬁcant factor in
their adherence to SMBG. In addition, “physical inﬂu-
ence” (i.e., patients’ reliance on their diabetes symptoms
in determining when to monitor) and “comorbidities”
were signiﬁcantly and positively associated with adher-
ence to SMBG among participants with type 2 diabetes;
whereas, “insurance coverage” was signiﬁcantly and 
positively associated with adherence to SMBG among
participants with type 1 diabetes. CONCLUSIONS: As
expected, differences exist between type 1 and type 2 
diabetics in SMBG adherence. While “environmental 
barriers” was a signiﬁcant factor in both groups, “phys-
ical inﬂuence” and “comorbidities” were only associated
with SMBG adherence among type 2 diabetics; and
“insurance coverage” among type 1 diabetics. Providing
glucose-monitoring recommendations with the under-
standing of these differences may be important in achiev-
ing optimal patient adherence to SMBG.
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A PROBLEM SHARED IS A PROBLEM HALVED?
COST ACCEPTABILITY OF SHARED CARE VS
HOSPITAL TREATMENT
Davies LM, O’Neill PK, Fargher EA, Symmons DP,Tricker K
Manchester University, Manchester, Gtr. Manchester, United
Kingdom
OBJECTIVE: To identify the costs and utility of sympto-
matic treatment using a shared model of care (SC) and
aggressive treatment using a hospital model of care (HT)
for established stable rheumatoid arthritis (duration >5
years) and estimate the relative cost acceptability of 
shared care. METHODS Data was obtained from 466
adults with established RA, who were enrolled into a 
randomised controlled trial of SC and HT and followed
for 36-months. A societal perspective was used; costs 
and outcomes were discounted at 3.5%, the recommended
UK Treasury rate. The primary outcome was quality
adjusted life years (QALY’s) measured by the EQ-5D 
questionnaire and population utility tariffs. Direct costs
were measured as resource use multiplied by published
national unit costs. An incremental cost utility ratio
(ICER) was estimated. Bootstrapping techniques were
used to derive net beneﬁt statistics and cost acceptability
curves and determine the probability that SC was cost
effective compared to HT. Sensitivity analysis was used to
assess the impact of alternative discount rates, alternative
methods of imputing missing and censored data and alter-
native sources of unit costs. RESULTS: SC is associated
with higher QALY’s and higher costs than HT, giving a
net cost of £1517/QALY gained. The probability that SC
was cost-effective was 0.89, over a £0 to £50,000 range
of cost/QALY threshold values. The probability that SC
was cost-effective ranged from 0.5 if decision makers are
prepared to pay £2000/QALY gained, to 0.8 for a thresh-
old of £13,000/QALY gained, to 0.9 for a threshold of
£42000/QALY gained. Sensitivity analysis showed that the
probability SC was cost effective was reduced if protocol
driven visits were included (p = 0.84) or censored data was
not imputed (p = 0.70). CONCLUSION: The primary and
sensitivity analyses indicate that shared care is likely to be
more cost-effective in the UK than hospital treatment in
70%-90% of cases.
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THE IMPACT OF TREATMENT MANAGEMENT
ALGORITHMS AND EVALUATED TIME HORIZON
ON ANTIVIRAL TREATMENT COSTS IN
CHRONIC HEPATITIS C
Siebert U1, Sroczynski G1,Wasem J2,Aidelsburger P3,
Rossol S4,Wong JB5
1Harvard University, Boston, MA, USA; 2University 
Duisburg-Essen, Essen, Germany; 3University of Greifswald,
Greifswald, Germany; 4University of Heidelberrg,
Ruesselsheim, Germany; 5Tufts University School of Medicine,
Boston, MA, USA
OBJECTIVES: To assess antiviral treatment (AVT) costs
associated with peginterferon alfa-2b plus ribavirin in
patients with chronic hepatitis C (CHC) in Germany.
Especially we focused on the impact of dose reduc-
tions/discontinuations, clinical management algorithms,
and future savings associated with the prevention of
advanced liver disease. METHODS: Clinical and drug
utilisation data were derived from a clinical trial (Manns,
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Lancet). Analysed treatment options were no antiviral
therapy (NoAVT), peginterferon alfa-2b plus ﬁxed dosage
of ribavirin (Peg-fR), and peginterferon alfa-2b plus
weight-based dosage of ribavirin (Peg-wbR). Examined
scenarios were: 1) full dosing AVT for 48 weeks (Full-
AVT); 2) stoppage of AVT in HCV-positive patients after
24 weeks (Stop-AVT); 3) consideration of AVT stoppage
algorithm plus actual dose reductions/ discontinuations
(Actual-AVT); and 4) net lifetime costs after subtracting
future savings due to prevented advanced liver disease
(Life). A validated Markov model (German Hepatitis 
C Model) was used to project future costs of CHC.
RESULTS: Full-AVT costs were €21,600 for Peg-fR and
€23,700 for Peg-wbR. Consideration of stoppage algo-
rithm and actual drug utilisation lead to 8%–33% reduc-
tions in expected AVT costs. In the lifetime analysis, AVT
costs were offset by savings from preventing future
disease by more than 85%, and incremental costs for AVT
were less than €2100. After applying a 3% annual dis-
count rate as recommended for pharmacoeconomic
studies (Life-D), future savings still offset AVT costs by
47% and the discounted lifetime costs for NoAVT, 
Peg-fR, and Peg-wbR were €14,100, €21,800, and
€22,400, respectively. CONCLUSIONS: Health policy
decision making for CHC should consider actual
expected AVT costs based on routine clinical management
algorithms and a time horizon beyond the ﬁrst year.
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END STAGE RENAL DISEASE IN FRANCE:
PLANNING EVOLUTION OF HEALTH CARE
NEEDS USING A MARKOV MODEL
Grenêche S1, d’Andon A1, Joseph A2, Landais P3
1JNB-Développement, Paris, France; 2Baxter SAS, Maurepas,
France; 3Hôpital Necker, Paris, France
OBJECTIVES: In European countries, incidence and
prevalence of End Stage Renal Disease (ESRD) are in-
creasing. Discrepancies between countries and regions
exist in the use of renal replacement therapies (RRT). 
Literature analysis, comparing haemodialysis (HD) to
peritoneal dialysis (PD) in terms of mortality/morbidity
and of patients’ preferences provides no evidence relative
to understanding differences in the provision of the
various treatments offered. Due to the high costs and
organizational issues of RRT, predicting future needs is
essential for nephrologists and Health care authorities.
Our aim was to project the impact of various therapeu-
tic strategies on the number of ESRD patients and their
distribution between existing dialysis techniques.
METHODS: We projected the ESRD incidence and
prevalence rates up until the year 2008. A Markov model
was built using data from French national registers
(French speaking PD register, French transplants organi-
zation) and speciﬁc surveys (Federation of non-proﬁt
private hospital establishments). Six Markov states were
deﬁned: No ESRD, in-centre HD (CHD), out-centre HD
(OCHD), PD, Transplantation (T) and Death (D). Tran-
sition probabilities were assessed considering a one-year
Markov cycle. A sensitivity analysis was performed on
fundamental assumptions. RESULTS: The number of
ESRD patients was projected to rise from 45,000 to
57,600, if 5% of incident patients at start of RRT were
treated by PD, 58% by HDC, 22% by OCHD, and 4%
transplanted. A substantial modiﬁcation of the initial 
distribution of incident patients was needed to have a 
signiﬁcant impact on the ﬁnal distribution of patients
between techniques. An increase of 5% to 20% of inci-
dent patients initially treated by PD, resulted in a rise
from 6.7% to 8.6% of prevalent patients ﬁnally treated
by that technique. CONCLUSIONS: ESRD is a French
Health care priority. This Markov model could be very
useful to planners in elaborating their Health care orga-
nizational schemes for the coming 5 years.
HP4
CHILDHOOD VACCINATION AGAINST
VARICELLA IN FRANCE: AN ECONOMIC
EVALUATION OF DIFFERENT STRATEGIES
Coudeville L, Brunot A
CRESGE—Université Catholique de Lille, Lille, France
OBJECTIVES: To determine the economic impact of
childhood varicella vaccination in France. METHODS:
This analysis is based on an epidemiological model of
VZV dynamics using Varivax efﬁcacy data. Epidemio-
logical and cost data (€2002) are based on French
sources. Three vaccination strategies have been analyzed
(S1: routine children vaccination alone, completed by 
S2: catch up program for 6 year-olds during 6 years, or
S3: massive catch up for 2–11 year-olds the ﬁrst year 
of vaccine marketing), for 3 vaccination coverage rates
(VCR), 45%, 70% and 90% achieved in 5 years. 
Perspectives considered are: societal perspective limited to
direct medical costs (SPD), or including indirect costs
(SPT), and Social Security perspective (SS). RESULTS:
Achieving a 90% VCR should yield, on a 50 years time
frame, a 85% decrease in varicella cases in average, and
prevent 27,000 to 33,000 varicella-related complications
annually (13,000 to 15,000 for a 45% VCR). Such a
program also leads in the base case to a decrease of total
costs (-52% for a 90% VCR), direct medical costs (-4%)
and SS costs (-10%) associated to varicella. The reduc-
tion of total costs is robust to the sensitivity analysis per-
formed; for SS perspective, the worst case scenario for
cost parameters leads to a cost per life year gained of
€6017 in 90% VCR. A massive catch up the ﬁrst year of
vaccine marketing is the one having the biggest impact on
varicella complications and costs: overall about (base
case) 80,000 additional complications prevented and a
saving of €147 million in total costs compared to routine
vaccination alone for a 90% VCR. CONCLUSION:
Routine childhood varicella vaccination in France is cost-
saving from all perspectives in the base case if high vac-
cination coverage is achieved, and remains cost-effective
in most conservative scenarios.
